– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection ...
Assembly Biosciences, Inc. reported progress in its clinical development of antiviral candidates, with data from multiple programs expected in 2025. Specifically, interim Phase 1b data for long-acting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback